

Dear Stakeholders,

With mixed emotions, I would like to inform you that this will be my last SOTC Newsletter as the C.E.O. of this great Company. As much as I would have liked to continue here forever, I am very happy that my father who is the founder and the current M.D. of the Company has decided to take a very well-deserved retirement after nurturing Alpa for almost 50 years with blood, sweat, and tears and along with his retirement, I have decided to try my hand at something new while I still can. Anyway, this Newsletter is supposed to be about the Company and there is great hope for the Company to reach unimaginable heights in the hands of the remaining management.

As indicated in the previous SOTC Newsletter of 04<sup>th</sup> January 2016, Alpa is in a very strong position to capitalize on several opportunities. As per the marketing and regulatory affairs teams, after having spent years of time, effort and money, Alpa may be just around the corner to enter the I.V. Fluids segment which many of our customers have been demanding for many years. The Company has also identified a highly reputable potential partner to make a foray in next generation biotechnology products including enzyme, probiotic, prebiotic and bio-similar products discussion for which are in advanced stage and details of which would be disclosed once finalized without violating confidentiality requirements.

That's it for now and I am sure that this Newsletter will continue with even greater vigor in pursuing the objectives as outlined in the SOTC Newsletter of 04<sup>th</sup> January 2016 and disseminating information of value.

Thank you. Jai Hind.  
Jayesh Patel, C.E.O.